Proven financial results backed by the efficient resource allocation and time-tested strategies
Revenue from operations
y-o-y
Earnings before interest, tax, depreciation and amortization (EBITDA)
y-o-y
Profit after tax (PAT)
y-o-y
Net cash
Significant operational progress underscored by robust sales, regulatory body approvals and geographic expansion
Domestic Sales Growth
US Business Sales Growth
Non-US Business Sales Growth
Domestic Business Growth Segments
Filings received approval until FY 2023-24 from USFDA ₹ 5,229 Mn R&D expenditure (Consolidated)
Prioritizing health and safety through comprehensive measures and ongoing trainings
Fatalities reported in FY 2023-24
EHS training conducted
Total man-days of EHS trainings
Mock drills conducted
Contributing towards community well-being through engaging initiatives
Lives benefited
Total investment towards CSR
Initiatives undertaken
Menu
